AmericaAnd MoreBusinessNew York NewsScience & TechnologyU.S. NewsUSA Herald Madrigal Pharmaceuticals Stock Skyrockets 200% After Positive Results for its Drug to Treat “Silent Disease” By Rochdi Rais - December 19, 2022 0 100 FacebookTwitterWhatsAppLinkedinEmail Madrigal is aiming to file for accelerated approval for resmetirom in the first half of 2023. Signup for the USA Herald exclusive Newsletter First Name Email Address: Leave this field empty if you're human: